June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Deep Sequencing as a Diagnostic Tool in Vitreoretinal Lymphoma
Author Affiliations & Notes
  • Charlene Choo
    Proctor Foundation, University of California San Francisco, San Francisco, California, United States
  • Matthew Regueiro
    Cleveland Clinic, Cleveland, Ohio, United States
  • Hans E Grossniklaus
    Emory Eye Center, Atlanta, Georgia, United States
  • John Alexander Gonzales
    Proctor Foundation, University of California San Francisco, San Francisco, California, United States
  • Steven Yeh
    University of Nebraska Stanley M Truhlsen Eye Institute, Omaha, Nebraska, United States
  • Armin Hinterwirth
    Proctor Foundation, University of California San Francisco, San Francisco, California, United States
  • Thuy Doan
    Proctor Foundation, University of California San Francisco, San Francisco, California, United States
  • Jessica Shantha
    Proctor Foundation, University of California San Francisco, San Francisco, California, United States
  • Footnotes
    Commercial Relationships   Charlene Choo None; Matthew Regueiro None; Hans Grossniklaus None; John Gonzales None; Steven Yeh Bausch + Lomb, Alcon, Code C (Consultant/Contractor); Armin Hinterwirth None; Thuy Doan None; Jessica Shantha None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 3274. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Charlene Choo, Matthew Regueiro, Hans E Grossniklaus, John Alexander Gonzales, Steven Yeh, Armin Hinterwirth, Thuy Doan, Jessica Shantha; Deep Sequencing as a Diagnostic Tool in Vitreoretinal Lymphoma. Invest. Ophthalmol. Vis. Sci. 2023;64(8):3274.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Vitreoretinal lymphoma (VRL) is the most common intraocular lymphoproliferative disorder, but it is difficult to diagnose due to inadequate diagnostic methods and the wide array of clinical manifestations that masquerade as uveitis. The purpose of our study is to compare the results of deep sequencing to that of conventional diagnostic tests to demonstrate its utility in the diagnosis of VRL.

Methods : Patients requiring vitrectomy for suspicion of VRL from the Emory Eye Center were prospectively enrolled for assessment of vitreous fluid with deep sequencing and conventional diagnostics, which included cytopathology, flow cytometry, and gene rearrangement on PCR, from September 2017 to June 2022. Data was collected on the patient’s medical history and ophthalmic exam. Deep sequencing was performed on vitreous samples at the Ralph and Sophie Heintz Laboratory at UCSF. Briefly, RNA extracted from 20-50µL of ocular fluid was used to prepare libraries and sequenced on the Illumina sequencing platform. Reads were analyzed using an in-house computational pipeline to detect mutations related to lymphoma against the Curated Online Somatic Mutations in Cancer Database.

Results : Thirteen patients (16 eyes) underwent a diagnostic vitrectomy for VRL. The cohort was 53.8% female and had a mean age of 67.2 years (range: 55-78 years). Seven patients had a history of B- or T-cell lymphoma prior to presenting with ophthalmic complaints.

Eight eyes (50%) were diagnosed with VRL. Deep sequencing detected pathogenic mutations associated with lymphoma in 5 eyes (62.5%), of which 3 eyes had the MYD88 mutation. One patient had vitreous biopsies in both eyes, which were negative on deep sequencing but positive on cytopathology for diffuse large B-cell lymphoma (DLBCL). One eye was presumed to be positive for DLBCL despite negative deep sequencing and conventional diagnostics because the fellow eye was positive for DLBCL on both deep sequencing and conventional diagnostics.

Eight eyes (50%) were not diagnosed with VRL based on clinical evaluation and diagnostic testing. Two eyes (12.5%) had pathogenic mutations on deep sequencing but were negative on conventional diagnostics. The remaining 6 eyes (37.5%) were negative for lymphoma on deep sequencing and conventional diagnostics.

Conclusions : Deep sequencing is a promising diagnostic tool for VRL as it can detect lymphoma-associated mutations using a small volume of intraocular fluid in an unbiased manner.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×